文献速递肝病消化道肿瘤与早癌

Resmetirom抑制MASH相关肝细胞癌及其MDK/LRP1机制

Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.
PubMed 文献 · Hepatology · 2026-01-12

本研究探讨Resmetirom对MASH相关肝细胞癌的治疗潜力及机制。在多种临床前模型中,Resmetirom显著抑制肿瘤;单细胞测序揭示HSC和dys-Heps高表达MDK,MDK通过LRP1促进M2巨噬细胞极化并经CXCL16-CXCR6轴导致T细胞耗竭。Resmetirom降低MDK并升高Thrb,与iMDK联用协同抑制肿瘤发生。

要点

  • Resmetirom在临床前MASH-HCC模型中显著抑制肿瘤并减轻脂肪变
  • MDK通过LRP1促进M2巨噬细胞极化,与MASH-HCC不良预后相关
  • Resmetirom与MDK抑制剂联用协同抑制肿瘤发生

核心结论

  • 靶向MDK/LRP1轴并使用Resmetirom是MASH相关HCC的潜在治疗策略,可同时改善代谢功能障碍和肿瘤进展。

研究设计与样本

  • 采用Western diet加CCl4诱导的小鼠MASH-HCC模型,并对肝脏和肿瘤组织进行单细胞RNA测序分析。
  • 在多种临床前模型中评估Resmetirom重定位治疗MASH-HCC的肿瘤抑制效果。

主要发现

  • Resmetirom在多种临床前模型中显著抑制肿瘤生长并减少脂肪变。
  • 肿瘤微环境中HSC和dys-Heps的MDK明显上调,MDK与人HCC较短的无复发生存相关,尤其见于非病毒、非酒精相关病例。
  • MDK通过LRP1促进M2样巨噬细胞极化,沉默巨噬细胞LRP1可消除MDK驱动的M2极化并增加细胞毒性细胞因子分泌。
  • LRP1阳性巨噬细胞通过CXCL16-CXCR6轴导致T细胞耗竭。
  • MDK表达与Thrb及脂解基因负相关,与脂肪生成基因正相关;Resmetirom降低MDK并升高Thrb。

临床怎么用

  • Resmetirom可能用于MASH相关HCC的治疗,尤其针对MDK/LRP1轴介导的代谢重编程和免疫抑制。
  • 联合MDK抑制剂可能增强Resmetirom的肿瘤抑制效果,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH)-associated hepatocellular carcinoma (HCC) are poorly understood, and effective treatments are lacking. This study explored the translational potential of Resmetirom, a clinically approved thyroid hormone receptor beta (Thrb) agonist, and investigated the mechanistic basis of MASH-associated hepatocarcinogenesis. APPROACH AND RESULTS: Repurposing Resmetirom for MASH-HCC treatment demonstrated significant tumor-suppressive effects across multiple preclinical models. To further investigate its mechanisms, we employed a Western diet plus CCl 4 -induced murine MASH-HCC model, complemented by single-cell RNA sequencing (scRNA-seq) analyses of liver and tumor tissues. These analyses revealed active cell-cell communication within the tumor microenvironment, particularly involving hepatic stellate cells (HSCs) and dysplastic hepatocytes (dys-Heps). These cells showed marked upregulation of midkine (MDK), which in human HCC correlated with shorter relapse-free survival, specifically in non-viral, non-alcohol-associated cases. In mouse models, MDK facilitated M2-like macrophage polarization via interaction with the receptor LRP1, contributing to disease progression from MASH to fibrosis and eventual HCC. Silencing LRP1 in macrophages abolished MDK-driven M2 polarization and increased cytotoxic cytokine secretion, while LRP1-positive macrophages contributed to T cell exhaustion through the CXCL16-CXCR6 axis. MDK expression negatively correlated with Thrb and lipolytic genes, but positively with lipogenesis genes. Resmetirom treatment not only significantly suppressed tumor growth and reduced steatosis but also decreased MDK expression and increased Thrb levels. Combining Resmetirom and an MDK inhibitor (iMDK) synergistically suppressed tumorigenesis in vivo. CONCLUSIONS: Targeting the MDK/LRP1 axis with Resmetirom offers a promising therapeutic strategy for MASH-associated HCC, addressing both metabolic dysfunction and tumor progression.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhang VX, Suoangbaji T, Tsui YM, et al. Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression. Hepatology. 2026. PMID: 41525571. doi:10.1097/HEP.0000000000001675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。